Talk:UK Oxford Timm K: Difference between revisions

From Bioblast
No edit summary
No edit summary
Line 5: Line 5:
|city=Oxford
|city=Oxford
|country=United Kingdom
|country=United Kingdom
|weblink=https://www.pharm.ox.ac.uk/research/timm-group
|Contact=Timm Kerstin
|Contact=Timm Kerstin
|Status=O2k 2021-
|Status=O2k 2021-
|keyword=Our research is in cardio-oncology, namely in the side effects of chemotherapy on the heart. We are particularly interested in how different classes of chemotherapeutics affect cardiac metabolism and energetics, and how cardioprotective agents may interfere with, or potentiate, anti-cancer action of chemotherapeutics. We thus use the O2k for HRR of cardiac muscle fibres, isolated cardiac mitochondria, tumour homogenates and cardiomyocytes and cancer cells. We also have collaborations in neuropharmacology and are happy to discuss potential collaborations across disciplines
}}
}}

Revision as of 11:32, 24 February 2022

                



Talk:UK Oxford Timm K

Oroboros O2k-Network

O2k-Network
O2k-Network Lab University of Oxford, Department of Pharmacology
Address Mansfield Road, OX1 3QT
City Oxford
State/Prov
Country United Kingdom
Weblink https://www.pharm.ox.ac.uk/research/timm-group
Contact Timm Kerstin
Team
Team previous
Status O2k 2021-
Oroboros Events
Topics Our research is in cardio-oncology, namely in the side effects of chemotherapy on the heart. We are particularly interested in how different classes of chemotherapeutics affect cardiac metabolism and energetics, and how cardioprotective agents may interfere with, or potentiate, anti-cancer action of chemotherapeutics. We thus use the O2k for HRR of cardiac muscle fibres, isolated cardiac mitochondria, tumour homogenates and cardiomyocytes and cancer cells. We also have collaborations in neuropharmacology and are happy to discuss potential collaborations across disciplines


O2k-Publications

update please

O2k-Abstracts

update please

Cookies help us deliver our services. By using our services, you agree to our use of cookies.